Average Ratings 0 Ratings
Average Ratings 0 Ratings
Description
BIOiSIMTM represents a groundbreaking 'virtual drug development engine' that significantly enhances the drug development sector by effectively identifying drug compounds that are most likely to provide meaningful therapeutic benefits for various diseases or conditions. We provide an array of translational solutions that are tailored to meet the specific needs of your pre-clinical and clinical initiatives. Central to our offerings is the highly validated BIOiSIMTM platform, which supports the development of small molecules, large molecules, and viruses. This innovative platform is underpinned by extensive data derived from thousands of compounds across seven different species, resulting in a level of robustness that is uncommon in the field. Emphasizing human health outcomes, the heart of the platform features a translatability engine that seamlessly converts insights gained from different species. Importantly, the BIOiSIMTM platform can be deployed prior to the initiation of preclinical animal trials, facilitating earlier insights and potentially reducing the costs associated with outsourced experimentation. By integrating these advanced capabilities, we aim to streamline the drug development process and accelerate the journey from discovery to market.
Description
The process of introducing a new medication to the market, starting from initial development to the final launch, is both time-intensive and heavily regulated, often spanning over a decade or more. Achieving success in this endeavor hinges on the timely availability of precise analytical data, which is essential for making informed decisions during the early stages of development and reducing the likelihood of setbacks later on. Modern drug development primarily follows a systematic approach, with the crucial first step usually being the identification of a biological target to concentrate efforts on. This target identification demands a comprehensive understanding of the characteristics of the candidates, enabling swift and reliable identification of the most promising options. After establishing a biological target, the next significant hurdle is identifying the most advantageous lead molecules, which entails discovering potential drug candidates—these may include small organic compounds or biological constructs with therapeutic capabilities. Thus, the entire journey from concept to market is a complex interplay of scientific insight and strategic decision-making.
API Access
Has API
API Access
Has API
Integrations
No details available.
Integrations
No details available.
Pricing Details
No price information available.
Free Trial
Free Version
Pricing Details
No price information available.
Free Trial
Free Version
Deployment
Web-Based
On-Premises
iPhone App
iPad App
Android App
Windows
Mac
Linux
Chromebook
Deployment
Web-Based
On-Premises
iPhone App
iPad App
Android App
Windows
Mac
Linux
Chromebook
Customer Support
Business Hours
Live Rep (24/7)
Online Support
Customer Support
Business Hours
Live Rep (24/7)
Online Support
Types of Training
Training Docs
Webinars
Live Training (Online)
In Person
Types of Training
Training Docs
Webinars
Live Training (Online)
In Person
Vendor Details
Company Name
VERISIMLife
Country
United States
Website
www.verisimlife.com/our-platform/
Vendor Details
Company Name
Bruker
Founded
1960
Country
United States
Website
www.bruker.com/en/applications/pharma/drug-discovery.html